Author: David Browne
-
Environmental Footprint part 2 – Getting started!
by
In most parts of Europe the pressure is on with regard to carbon and moving towards net zero. This is no longer a “nice-to-do” thing that creates positive PR – it is now a “must-do”. An example is the UK NHS insistence on seeing a company’s carbon reduction plan in order to be considered as…
-
Environmental Footprint & Sustainability – explained simply!
by
The NHS has the target of being carbon net zero by 2040 and, as the customer of all UK-based pharma companies, the industry must respond to that target to align with our customer in order to be considered a supplier for the future. There is another side to this: we do have breakthroughs in orphan…
-
Environmental Focus & Sustainability – Building a compelling & compliant strategy & communication
by
Challenge: All companies feel compelled to talk about environmental focus and there is a danger that this can seem like “green-washing”. The NHS has a goal of becoming carbon net zero by 2040 and it has a focus on respiratory inhalers and gaseous anaesthetics as major contributor to the issue. We needed to develop a…
-
Feasibility of Nordic launch > Strategies for launch
by
Challenge: The Nordic affiliate of a European pharma company needed advice on the feasibility of launching two related branded generics (or alternative brands) into the four major Nordic markets. Assuming there was opportunity they sought strategic advice on how to launch most effectively.
-
Education and Strategic Marketing
by
4th June 2024 saw the EMIG HR group meet and our Managing Director & Lead Consultant, David Browne, present having been invited by the Chair of the Group, Dr Jim Golby. We love our marketing, commercial and go-to-market projects but we are always open to supporting and educating others. We did a session in a…
-
New product feasibility, forecasting & P&L > go-to-market & launch strategy
by
Challenge: A pharma company headquartered in Asia Pacific wanted to assess feasibility, go-to-market and launch strategy for a brand that would be the first licensed medicine to treat an increasingly recognised condition in women’s health in the UK. This would assist their decision making and BD process.
-
New product launch > Portfolio strategy and positioning
by
Challenge: The UK affiliate of an international pharma company was launching two new brands and, in doing so, it was creating a portfolio in this therapy area. The new portfolio needed a strategy, positioning and messaging. New and existing brands needed their own story within the overall portfolio communication.
-
Digital Transformation and Omnichannel
by
As Consultants it is important to be up to date with not just the latest movements but also market changes that could be predicted to happen. The month of May saw us attend two interesting events in the digital space. TikTok …. A word (a word?) that puts fear into the heart of compliance teams!…
-
Feasibility of entering the UK market > Go-to-market strategy
by
Challenge: A well established healthcare company headquartered in mainland Europe wanted to understand the feasibility of entering the UK market and, if viable, the best go-to-market strategy for its range of OTX products in the women’s health space.
